NZ740956A - Reversing the effects of the tumor microenvironment using chimeric cytokine receptors - Google Patents

Reversing the effects of the tumor microenvironment using chimeric cytokine receptors

Info

Publication number
NZ740956A
NZ740956A NZ740956A NZ74095612A NZ740956A NZ 740956 A NZ740956 A NZ 740956A NZ 740956 A NZ740956 A NZ 740956A NZ 74095612 A NZ74095612 A NZ 74095612A NZ 740956 A NZ740956 A NZ 740956A
Authority
NZ
New Zealand
Prior art keywords
reversing
effects
tumor microenvironment
cytokine receptors
chimeric cytokine
Prior art date
Application number
NZ740956A
Inventor
Ann Leen
Juan Vera
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Priority claimed from NZ723731A external-priority patent/NZ723731A/en
Publication of NZ740956A publication Critical patent/NZ740956A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An immune system cell comprising a chimeric cytokine receptor comprising a cytokine-binding exodomain and a signal transducing endodomain, wherein (a) the exodomain comprises an IL-13 cytokine binding exodomain and an IL-7 signal transducing endodomain. Further discloses treatment of cancer.
NZ740956A 2011-04-08 2012-04-05 Reversing the effects of the tumor microenvironment using chimeric cytokine receptors NZ740956A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473457P 2011-04-08 2011-04-08
NZ723731A NZ723731A (en) 2011-04-08 2012-04-05 Reversing the effects of the tumor microenvironment using chimeric cytokine receptors

Publications (1)

Publication Number Publication Date
NZ740956A true NZ740956A (en) 2020-03-27

Family

ID=69957764

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ740956A NZ740956A (en) 2011-04-08 2012-04-05 Reversing the effects of the tumor microenvironment using chimeric cytokine receptors

Country Status (1)

Country Link
NZ (1) NZ740956A (en)

Similar Documents

Publication Publication Date Title
NZ723731A (en) Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
PH12019502411A1 (en) Cells expressing chimeric activitaing receptors and chimeric stimulating receptors and uses thereof
WO2012127464A3 (en) Constitutively activated t cells for use in adoptive cell therapy
MX2019013204A (en) Chimeric cytokine receptor.
MX2019010974A (en) Fc-optimized anti-cd25 for tumour specific cell depletion.
MX2020007021A (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor.
WO2012150822A3 (en) Method for receiving downlink signal, and user device, and method for transmitting downlink signal, and base station
MX2019006631A (en) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells.
MX2020001450A (en) Methods and compositions for reducing immunosupression by tumor cells.
EP3467101A3 (en) Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
MX2014010183A (en) Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer.
MY164661A (en) Novel immunoconjugates
MX349662B (en) Anti-tumor antigen antibodies and methods of use.
ZA201204855B (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
MX2012003521A (en) Insulin receptor binding antibodies.
MX2012001417A (en) Fully human antibodies to btla.
NZ612512A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
NZ626610A (en) Antibodies that bind csf1r
EP2781035A4 (en) Method and apparatus for transmitting and receiving signals in multi-antenna communication system
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
MX343659B (en) Fc RECEPTOR BINDING PROTEINS.
MX2012012493A (en) Modified pyr/pyl receptors activated by orthogonal ligands.
MX343580B (en) Antibodies against g-csfr and uses thereof.
GB2492016A (en) Acoustic transducer with a liquid-filled porous medium backing and methods of making and using same
HK1182745A1 (en) Methods and systems for generating, validating and using monoclonal antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 05 APR 2022 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20201007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2023 BY CPA GLOBAL

Effective date: 20220519

LAPS Patent lapsed